RxDoctor Payments Data

Ann Schmitt, DO

Family Medicine · Mooresville, INNPI 1801359666

Payments from drug & device makers

$432in general payments, 2019–2025

Across 25 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$45
  • Exact Sciences$39
  • Otsuka America Pharmaceutical, Inc.$35
  • Baxter Healthcare$31
  • Sanofi-aventis U.S. LLC$31
  • AbbVie$31
  • plus $219 from 11 others

What the payments were for

  • Food & beverage$40093%
  • Other$317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$432 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$31,091
Medicare patients
134
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$66,658
TrulicityDulaglutide60$64,584
MounjaroTirzepatide41$42,799
EliquisApixaban33$41,088
JardianceEmpagliflozin37$36,621
FarxigaDapagliflozin Propanediol17$15,455
Tresiba Flextouch U-200Insulin Degludec11$14,942
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,238
JanuviaSitagliptin Phosphate14$12,224
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$11,932
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$9,801
Breo ElliptaFluticasone/Vilanterol14$5,086
PaxlovidNirmatrelvir/Ritonavir11$4,213
Gabapentin173$1,941
Fluoxetine Hcl41$1,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$16$107,798115 claims
Novo NordiskOzempic$17$66,65859 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$28$31,25655 claims
AstraZenecaFarxiga$18$15,45517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Mooresville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →